Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats

被引:75
作者
Li, JL [1 ]
Mori, S [1 ]
Kaji, Y [1 ]
Kawanishi, J [1 ]
Akiyama, T [1 ]
Norimatsu, H [1 ]
机构
[1] Kagawa Med Univ, Dept Orthoped Surg, Kagawa 7610793, Japan
关键词
bisphosphonate; fracture healing; drug concentration; osteoclast; histomorphometry;
D O I
10.1359/jbmr.2000.15.10.2042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the present study was to investigate effects of incadronate on early stages of fracture healing and to detect its concentration in callus area (Ca.Ar), Rats were injected three times per week with either two doses of incadronate (10 mu g/kg and 100 mu g/kg) or vehicle for 2 weeks. Femora were then fractured and fixed and animals were divided into pretreatment (P-10 and P-100) and continuous treatment (C-10 and C-100) groups, Incadronate treatment was stopped in P-10 and P-100 groups but continued in C-10 and C-100 groups. Animals were killed at 2 weeks and 4 weeks after fracture. Results showed significantly large callus, compared with the control, only in C-100 group at 4 weeks but not at 2 weeks. Both linear labeled surface (LS) and eroded surface (ES) decreased significantly in C-10 and C-100 groups at 2 weeks and 4 weeks. Osteoclast number (N.Oc) decreased significantly in C-10 and C-100 groups at 2 weeks but increased slightly at 4 weeks. However, there was no significant difference in the above parameters in P-10 and P-100 groups at 4 weeks. Apoptotic osteoclasts were observed only in the C-100 group at 4 weeks. A time-course decrease in incadronate concentration was detected in P-10 and P-100 groups whereas an increase was observed in C-10 and C-100 groups. These findings suggest that larger callus under incadronate treatment may result from the inhibition of bone resorption, histological characteristics of callus may be correlated with incadronate concentration, and metabolism of incadronate in bone may be related to the rate of bone turnover.
引用
收藏
页码:2042 / 2051
页数:10
相关论文
共 43 条
[1]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[2]   EFFECTS OF DISODIUM ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE (EHDP) ON INTERLEUKIN-1 PRODUCTION BY MACROPHAGES [J].
AIDA, Y ;
TODA, Y ;
SHIMAKOSHI, Y ;
YAMADA, K ;
AONO, M .
MICROBIOLOGY AND IMMUNOLOGY, 1986, 30 (11) :1199-1206
[3]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[4]  
BOONEKAMP PM, 1986, BONE MINER, V1, P27
[5]   Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis [J].
Chavassieux, PM ;
Arlot, ME ;
Reda, C ;
Wei, L ;
Yates, AJ ;
Meunier, PJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1475-1480
[6]  
Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
[7]   AMINOALKYLBISPHOSPHONATES, POTENT INHIBITORS OF BONE-RESORPTION, INDUCE A PROLONGED STIMULATION OF HISTAMINE SYNTHESIS AND INCREASE MACROPHAGES, GRANULOCYTES, AND OSTEOCLASTS INVIVO [J].
ENDO, Y ;
NAKAMURA, M ;
KIKUCHI, T ;
SHINODA, H ;
TAKEDA, Y ;
NITTA, Y ;
KUMAGAI, K .
CALCIFIED TISSUE INTERNATIONAL, 1993, 52 (03) :248-254
[8]   Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [J].
Fisher, JE ;
Rogers, MJ ;
Halasy, JM ;
Luckman, SP ;
Hughes, DE ;
Masarachia, PJ ;
Wesolowski, G ;
Russell, RGG ;
Rodan, GA ;
Reszka, AA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :133-138
[9]   Bisphosphonates: Mechanisms of action [J].
Fleisch, H .
ENDOCRINE REVIEWS, 1998, 19 (01) :80-100
[10]   BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE [J].
FLEISCH, H .
DRUGS, 1991, 42 (06) :919-944